A strategic financial analysis of iPSC-based manufacturing
vs. autologous models
Author: Astrid Van Damme, PhD, MBA– Head of Program Management
Executive summary
Cell therapy is moving from specialist, hospital-bound delivery toward broader patient access and the manufacturing model chosen at the outset sets the operational and commercial ceiling for any program. Autologous therapies remain structurally constrained by one-batch-per-patient production, vein-to-vein logistics, capacity bottlenecks and patient attrition during manufacturing and quality control (QC) timelines. Alternatively, traditional allogeneic approaches improve scale, but are limited by donor variability and finite expansion. In this report, we demonstrate how induced pluripotent stem cell (iPSC)-based platforms, anchored by a renewable master cell bank (MCB), enable standardized off-the-shelf inventory and true industrial scaling. This modality shift delivers a transformational economic advantage: potentially driving up to a 95% reduction in cost of goods sold (COGS) compared to autologous baselines. To actualize this potential, Cellistic developed Echo™-NK, an end-to-end good manufacturing practice (GMP) manufacturing platform for iPSC-derived natural killer (NK) cell therapies. Analysis of this framework demonstrates a shift from labor-driven to materials-driven COGS and around 40% relative cost compression at commercial scale, with unit economics most sensitive to batch yield and facility utilization
Download the white paper